What Gentronix does

Gentronix is a UK-based contract research organization (CRO) specializing in genetic toxicology testing, founded in 1999 as a spinout from the University of Manchester Institute of Science and Technology (UMIST). The company provides in vitro and in vivo assays that assess DNA damage, gene mutations, and chromosomal alterations for pharmaceutical, biotechnology, chemical, and agrochemical companies. Its service portfolio spans early-stage predictive screening (GreenScreen GC and GreenScreen HC assays, introduced in 2003 and 2005) through GLP-compliant regulatory studies, including a comprehensive Ames test menu, micronucleus tests, mouse lymphoma assays, and the in vivo Big Blue® transgenic rodent gene mutation assay (acquired from Merck KGaA in 2021) and DuplexSeq™ error-corrected sequencing mutagenesis assays (acquired from TwinStrand Biosciences in 2025, with Scantox as the sole global provider). All studies are validated against OECD protocols and conducted under MHRA GLP accreditation.\n\nThe business operates as a B2B sales-led CRO with custom, quote-based study pricing and multi-year contract structures. A dedicated business development team engages directly with current and prospective enterprise customers to coordinate research programs, and the unit's scientific staff of 65+ colleagues — including leadership with 20+ years of regulatory genetic toxicology experience — provides study design and data interpretation as part of the value proposition. Marketing is conducted through peer-reviewed publications, industry events, and direct enterprise engagement rather than inbound digital channels.\n\nIn September 2024, Gentronix was acquired by Scantox Group, a Danish preclinical research provider, and the business was fully rebranded as Scantox Manchester in March 2026, integrating its genetic toxicology capabilities into Scantox's broader discovery, in vivo, and CNS/neurology service portfolio. The rebrand enables cross-sell into Scantox's global client base, including localizations in Korea and Japan, and positions the unit within a multi-site European preclinical platform.

Name

Gentronix

Legal name

Gentronix Limited

Website

https://gentronix.co.uk

Company type

Private

Founded year

1999

Operating status

Acquired

Headcount range

11–50 employees

Short description

Gentronix is a UK-based genetic toxicology CRO providing GLP-compliant in vitro and in vivo assays for pharmaceutical, biotech, chemical, and agrochemical companies. Acquired by Scantox Group in 2024 and now operating as Scantox Manchester.

Ownership category

akta.pro rank

Product category

Genetic Toxicology Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genetic Toxicology (Ames/Micronucleus/Comet) (HLAGAFAE)

akta.pro secondary industries

GLP Toxicology (Repeat-Dose, Acute/Subacute) (HLAGAFAD), In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

Keywords

• Genetic toxicology testing
• Contract research services
• GLP-compliant assays
• In vivo mutation testing
• Regulatory safety assessment

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: B2B contract research organization providing genetic toxicology testing services to pharmaceutical, biotech, chemical, and agrochemical industries. Services include GLP-compliant studies and regulatory submission support.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Gentronix provides GLP-compliant genetic toxicology contract research services, offering in vitro and in vivo assays that detect DNA damage, gene mutations, and chromosomal alterations for pharmaceutical, biotechnology, chemical, and agrochemical clients. Its portfolio spans early predictive screening (GreenScreen HC/GC), core regulatory assays (Ames tests, micronucleus, mouse lymphoma), and advanced in vivo mutation analysis (Big Blue®, DuplexSeq™), with custom study design and regulatory submission support.

Differentiator

Problem solved

Functional benefit

Products and services

• Big Blue® Transgenic Rodent Gene Mutation Assay OECD 488-compliant in vivo transgenic rodent gene mutation assay (somatic and germ cell) for assessing gene mutations in pharmaceuticals, chemicals, and agrochemicals; offered as GLP-compliant contract research with MHRA approval.
• GreenScreen HC Predictive Genotoxicity Assay Predictive genotoxicity screening assay used as an early-stage screen for DNA damage in drug and chemical development pipelines, serving pharmaceutical and chemical industry clients.
• GreenScreen GC Predictive Genotoxicity Assay Early predictive genotoxicity screening assay that detects genotoxic activity in test compounds, used by pharmaceutical and chemical developers to triage candidates before full regulatory testing.
• DuplexSeq™ Mutagenesis Assays Error-corrected next-generation sequencing mutagenesis assays for highly sensitive detection of rare mutations, offered as a specialist genomic safety service to pharmaceutical and chemical clients; Scantox is the sole provider.
• Ames Test Portfolio Comprehensive suite of bacterial reverse mutation (Ames) tests used to assess the mutagenic potential of drug candidates, chemicals, and agrochemicals; GLP-compliant and OECD-validated for regulatory submissions.
• Enhanced Ames Test Program Expanded Ames testing program with enhanced throughput and accuracy, designed to scale capacity for pharmaceutical, chemical, and agrochemical genotoxicity testing programs.

Quantifiable outcome

• Scantox positioned as sole provider of DuplexSeq Mutagenesis Assays following TwinStrand Biosciences acquisition

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• TwinStrand BiosciencescoreTechnology or Integration · 1 January 2025Scantox Group acquired the DuplexSeq nonclinical genomic safety business from TwinStrand Biosciences, positioning Scantox as the sole provider of DuplexSeq Mutagenesis Assays.
• Scantox GroupcoreStrategic or Co-development Partner · 9 September 2024Scantox Group, a Danish preclinical research provider, acquired Gentronix Ltd in September 2024. The acquisition expanded Scantox's genetic toxicology capabilities and service offerings. Gentronix now operates as Scantox Manchester under the Scantox brand.
• Merck KGaAcoreTechnology or Integration · 1 January 2021Gentronix acquired the transgenic mutation assay (Big Blue® TGRA model) from Merck KGaA in 2021, achieving MHRA GLP approval and market acceptance. This acquisition enabled Gentronix to add in vivo genotoxicology services.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Inotiv: Inotiv (formed from Envigo and CRL's research models business) provides preclinical safety assessment including genetic toxicology alongside research models and contract research services to pharma and chemical customers.
• Wuxi AppTec: Wuxi AppTec's preclinical and safety assessment business includes genetic toxicology services as part of its integrated discovery-to-commercial platform for global pharma and biotech sponsors, making it a broad incumbent competitor.
• Charles River Laboratories: Charles River is a global preclinical CRO with established genetic toxicology, in vitro and in vivo safety, and regulatory support capabilities. It competes with Gentronix for pharma and chemical gen tox work but as part of a much broader discovery-through-manufacturing portfolio.
• Labcorp Drug Development (Covance): Labcorp Early Development offers genetic toxicology services alongside a full suite of preclinical, clinical, and central lab offerings, addressing the same enterprise pharma and chemical customers as Gentronix with a substantially broader solution set.
• Eurofins Scientific: Eurofins provides genetic toxicology, regulatory safety testing, and product compliance services through its pharma and biopharma product testing divisions, serving overlapping pharmaceutical, chemical, and agrochemical clients across global markets.

Direct peers

• BioReliance (MilliporeSigma): MilliporeSigma's BioReliance business is a direct genetic toxicology and biosafety testing services provider, offering Ames, micronucleus, MLA, and in vivo transgenic mutation assays to pharma, biotech, and agrochemical sponsors — directly overlapping with Gentronix's service portfolio and customer base.
• ITR Canada: ITR Canada is a specialized genetic toxicology CRO offering GLP-compliant in vitro and in vivo genotoxicity assays to pharma and chemical clients — a close peer in niche, methodology, and regulatory focus.
• MB Research Laboratories: MB Research Laboratories provides GLP genetic toxicology and nonclinical safety testing services for pharmaceutical, biotech, chemical, and consumer products companies — directly comparable in service breadth and customer mix to Gentronix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gentronix-limited
• Xx.com/GentronixLtd

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gentronix